The Medical Letter on Drugs and Therapeutics
Drugs for Atopic Dermatitis
June 15, 2020 (Issue: 1600)Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving...more
- W Frazier and N Bhardwaj. Atopic dermatitis: diagnosis and treatment. Am Fam Physician 2020; 101:590.
- R Tanei. Atopic dermatitis in older adults: a review of treatment options. Drugs & Aging 2020; 37:149.
- EJ van Zuuren et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev 2017; 2:CD012119.
- JR Chalmers et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet 2020; 395:962.
- L Davallow Gahar et al. Low risk of adrenal insufficiency after use of low- to moderate-potency topical corticosteroids for children with atopic dermatitis. Clin Pediatr (Phila) 2019; 58:406.
- EC Siegfried et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr 2016; 16:75.
- LF Eichenfield et al. Guidelines of care for the management of atopic dermatitis: section 2. management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71:116.
- JA Broeders et al. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience. J Am Acad Dermatol 2016; 75:410.
- J Castellsague et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitiudinal Lymphoma and Skin Cancer Evaluation – JOELLE study). Clin Epidemiol 2018; 10:299.
- Crisaborole (Eucrisa) for atopic dermatitis. Med Lett Drugs Ther 2017; 59:34.
- AS Paller et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016; 75:494.
- A Ahmed et al. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal. Br J Dermatol 2018; 178:659.
- LF Eichenfield et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol 2017; 77:641.
- J Schlessinger et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol 2020; 21:275.
- R Sidbury et al. Guidelines of care for the management of atopic dermatitis: section 3. management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71:327.
- FM Garritsen et al. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol 2014; 170:501.
- M Boguniewicz et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract 2017; 5:1519.
- EW Seger et al. Relative efficacy of systemic treatments for atopic dermatitis. J Am Acad Dermatol 2019; 80:411.
- Dupilumab (Dupixent) for moderate to severe atopic dermatitis. Med Lett Drugs Ther 2017; 59:64.
- EL Simpson et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335.
- EL Simpson et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156:44.
- A Blauvelt et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet 2017; 389:2287.
- M de Bruin-Weller et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018; 178:1083.
- CA Utine et al. Ocular surface disease associated with dupilumab treatment for atopic diseases. Ocul Surf 2020 May 18 (epub).
- Z Ou et al. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol 2018; 54:303.
- A Soria et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol 2019; 155:1312.
- J Schmitt et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol 2010; 162:661.
- AM Drucker et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol 2020 Apr 22 (epub).
- C Goujon et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial. J Allergy Clin Immunol Pract 2018; 6:562.
- ME Schram et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011; 128:353.
- K Phan and SD Smith. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J Dermatolog Treat 2019 Aug 1 (epub).
- AM Drucker et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol 2018; 178:768.
- U Matterne et al. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. Cochrane Database Syst Rev 2019; 1:CD012167.
- M Napolitano et al. Profile of baricitinib and its potential in the treatment of moderate to severe atopic dermatitis: a short review on the emerging clinical evidence. J Asthma Allergy 2020; 13:89.
- E Guttman-Yassky et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145:877.
- AM Montilla et al. Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther (Heidelb) 2019; 9:655.
- D Deleanu and I Nedelea. Biological therapies for atopic dermatitis: an update (review). Exp Ther Med 2019; 17:1061.
- E Guttman-Yassky et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol 2020; 156:411.
- JI Silverberg et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol 2020; 145:173.
- M Abrouk et al. Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol 2017; 77:177.
- Drugs for irritable bowel syndrome. Med Lett Drugs Ther 2020; 62:41.
- A Makrgeorgou et al. Probiotics for treating eczema. Cochrane Database Syst Rev 2018; 11:CD006135.
- P Rizk et al. Allergen immunotherapy and atopic dermatitis: the good, the bad, and the unknown. Curr Allergy Asthma Rep 2019; 19:57.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.